Patients Specialty medication access hinges on a 48-hour window The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes.
Market Access The critical importance of payer-provider collaboration goes... The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January.
News Novartis raises forecasts for three key growth products Novartis raises sales expectations for three growth products – Kesimpta, Scemblix, and Leqvio – by $4bn as it sets a 5% midterm revenue growth target.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.